The Latest Breaking News from BSX

Boston Scientific shows impressive growth in Q3 results, garnering bullish analyst support despite clinical trial setbacks.

With Boston Scientific gearing up to release its third-quarter earnings later this month, analysts expect double-digit earnings growth.

Boston Scientific recently reached an all-time high, outperforming the S&P 500 Index, with Wall Street analysts remaining bullish about the stock’s prospects.

Boston Scientific has significantly outperformed the broader market YTD, and Wall Street analysts are still bullish about the stock’s prospects.

The medical devices and equipment industry is primed to make significant strides toward growth this year, a surge propelled by increasing incidences of chronic diseases and the emphasis on early detection and treatment, coupled with leaps in technological development. Given this backdrop, let’s compare medical device stocks Boston Scientific (BSX)…

Coupled with the macroeconomic headwinds, the U.S. debt default crisis and consequent recessionary fears have triggered market volatility. Against this backdrop, quality growth stocks Boston Scientific (BSX), Cardinal Health (CAH), Cidara Therapeutics (CDTX), and Geospace Technologies (GEOS) could be solid buys now. Read on….

Boston Scientific (NYSE:BSX) has outperformed the market over the past 10 years by 9.66% on an annualized basis producing an average annual return of 20.68%. Currently, Boston Scientific has a market capitalization of $54.31 billion.

Boston Scientific Corporation (NYSE:BSX) has agreed to purchase Synergy Innovation Co Ltd's majority stake (~64%) of M.I.Tech Co Ltd, a publicly-traded Korean manufacturer, and distributor of medical devices for endoscopic and urologic procedures.  The deal is valued at KRW 14,500 per share, representing KRW 291.2 billion or approximately $230 million. M.I.Tech offers HANAROSTENT technology, a…

Boston Scientific (NYSE:BSX) has outperformed the market over the past 10 years by 9.09% on an annualized basis producing an average annual return of 20.41%. Currently, Boston Scientific has a market capitalization of $53.12 billion.